辅助雾化吸入对多黏菌素B血浆AUC/MIC与临床疗效关联的影响
本研究为前瞻性观察性队列,纳入43例接受多黏菌素B≥48h的危重多重耐药革兰阴性菌感染患者,比较静脉单用与静脉联合雾化吸入。群体药代动力学模型显示典型清除率为2.61 L/h。总体队列中AUCss,24h/MIC与疗效无关,但静脉单用组 responders 的AUCss,24h/MIC显著更高(P=0.005),ROC提示探索性阈值94.4;联合雾化组无暴露-反应关系。
要点
- 静脉单用多黏菌素B时,血浆AUCss,24h/MIC与临床疗效相关,探索性阈值为94.4。
- 静脉联合雾化吸入时,未观察到血浆暴露与疗效的关联。
- 加入雾化吸入后,应谨慎应用基于血浆的药代动力学/药效学靶值。
核心结论
- 血浆AUCss,24h/MIC与静脉单用多黏菌素B的临床疗效相关,但与静脉联合雾化吸入方案无关,可能因肺部暴露较高所致。
研究设计与样本
- 前瞻性观察性队列研究,纳入43例接受多黏菌素B≥48h的危重多重耐药革兰阴性菌感染成人,分为静脉组(n=22)和静脉联合雾化组(n=21)。
- 用NONMEM建立群体药代动力学模型,血浆样本经HPLC-MS/MS分析,治疗结束时盲法评估临床疗效。
主要发现
- 总体临床成功率为66.7%。
- 二室群体药代动力学模型最佳,典型清除率为2.61 L/h,肌酐清除率和总胆汁酸为显著协变量。
- 总体队列中,临床成功与失败组间AUCss,24h和AUCss,24h/MIC无显著差异(P=0.591和0.143)。
- 静脉单用组中, responders 的AUCss,24h/MIC显著更高(P=0.005),ROC分析提示探索性疗效阈值为94.4;AUCss,24h呈非显著趋势(P=0.076)。
- 静脉联合雾化组未观察到暴露-反应关系(P=0.398和0.495)。
临床怎么用
- 静脉单用多黏菌素B时可参考血浆AUCss,24h/MIC与疗效的关联,但探索性阈值94.4需进一步验证。
- 联合雾化吸入时,不宜直接套用基于血浆的药代动力学/药效学靶值指导 dosing。
局限性
- 样本量小(共43例),探索性阈值需外部验证。
- 观察性设计可能存在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To develop a population pharmacokinetic (PPK) model of polymyxin B for intravenous (IV) and combined intravenous plus inhaled (IV + IH) administration in critically ill patients, and evaluate the association between plasma 24-h steady-state area under concentration-time curve to minimum inhibitory concentration ratio (AUCss,24h/MIC) and clinical outcomes. METHODS: In this prospective observational cohort study, adults with multidrug-resistant Gram-negative bacterial infections receiving polymyxin B ≥ 48 h were enrolled and assigned to IV or IV + IH groups. Plasma samples were analysed by validated HPLC-MS/MS. PPK models were developed with NONMEM. Clinical efficacy at the end of treatment was blindly assessed. RESULTS: Forty-three patients were enrolled (IV, n = 22; IV + IH, n = 21), with an overall clinical success rate of 66.7%. A two-compartment PPK model best described the data. The typical clearance was 2.61 L/h, with creatinine clearance and total bile acids identified as significant covariates. In the overall cohort, no significant differences in AUCss,24h or AUCss,24h/MIC were observed between clinical success and failure (P = 0.591 and 0.143, respectively). In the IV group, AUCss,24h/MIC was significantly higher in responders (P = 0.005), and an ROC analysis suggested an exploratory efficacy threshold of 94.4; AUCss,24h showed a non-significant trend (P = 0.076). No exposure-response relationship was observed in the IV + IH group (P = 0.398 and 0.495, respectively). CONCLUSIONS: Plasma AUCss,24h/MIC appears to be associated with clinical efficacy during IV monotherapy but not in IV + IH regimens, possibly due to high pulmonary exposure. Plasma-based PK/PD targets should be applied cautiously when inhalation is added.
引用
- Zhang S, Li Y, Tan H, et al. Effect of adjunctive inhalation on the association between plasma AUC/MIC of polymyxin B and clinical efficacy in MDR gram-negative infections. J Antimicrob Chemother. 2026. PMID: 42446384. doi:10.1093/jac/dkag238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。